Wells Fargo
FOLD

Wells Fargo’s Amicus Therapeutics FOLD Stock Holding History

Wells Fargo’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-59,700
Closed -$167K – 6454
2018
Q2 		$167K Buy
+59,700
New +$902K ﹤0.01% 5131

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Wells Fargo's FOLD Position: Q1 2026 in Review

Wells Fargo reduced its Amicus Therapeutics (FOLD) stake by 67% in Q1 2026, selling an estimated $3.27M and leaving 111,070 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #3433.

Wells Fargo first reported a position in FOLD in Q2 2013 and has held it in 47 quarters since. The position peaked at $42.5M in Q1 2018. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Wells Fargo held 111,070 shares of Amicus Therapeutics worth $1.61M as of Q1 2026.
  • Wells Fargo sold 228,356 Amicus Therapeutics shares in Q1 2026, an estimated $3.27M.
  • Amicus Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3433 holding.
  • Wells Fargo first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 47 quarters since.
  • Wells Fargo's Amicus Therapeutics position peaked at $42.5M in Q1 2018.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.